Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cance...
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
About this item
Full title
Author / Creator
Publisher
New York: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
The homologous recombination deficiency (HRD) score integrates three DNA-based measures of genomic instability, and has been understudied in prostate cancer. Given the recent FDA approval of two PARP inhibitors for prostate cancer, HRD score analysis could help to refine treatment selection. We assessed HRD score (defined as the sum of loss-of-hete...
Alternative Titles
Full title
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8154637
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8154637
Other Identifiers
ISSN
0893-3952
E-ISSN
1530-0285
DOI
10.1038/s41379-020-00731-4
